Esophageal Squamous Cell Carcinoma
Conditions
Brief summary
The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.
Interventions
BIOLOGICALSintilimab
Other Name: (IBI308)
carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
RADIATIONRadiation
IMRT or VMAT
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed esophageal squamous carcinoma * 18≤age≤75 * ECOG PS is 0-1 * TanyN+M0 or T3-4NanyM0 tumors * Patients must have surgically resectable disease treatable by esophagectomy, as assessed by a thoracic surgeon * No prior chemotherapy,radiotherapy and immunotherapy * Disease must be clinically limited to the esophagus * No esophageal perforation and no active esophageal bleeding * No interstitial pneumonia or history of interstitial pneumonia * FEV1\>1.2L * Adequate organ function defined at baseline as: WBC ≥3,000/ L，ANC ≥1,500/ L，Platelets ≥100,000/ L，Hb ≥9 g/dl； Calculated creatinine clearance \>40 ml/min using Cockcroft-Gault method: Males: Creatinine CL = Weight (kg) x (140 - Age) . (mL/min) 72 x serum creatinine (mg/dL)Female：Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)；Total serum bilirubin ≤1.5 mg/dL， AST/ALT ≤2.5× upper limit of normal，Mean QT interval corrected for heart rate (QTc) \<470 ms calculated from 3 ECGs using Frediricia's Correction * Able to provide written informed consent * Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Exclusion criteria
* Previous treatment with chemotherapy, radiotherapy or immunotherapy * Cervical esophageal cancer * Esophageal perforation or active esophageal bleeding * Interstitial pneumonia or history of interstitial pneumonia * Patients with evidence of metastatic disease * Chronic Hepatitis B or C infection (e.g. Hepatitis B surface Ag positive or detectable viral load for Hepatitis B or C). Patients with prior evidence of Hepatitis B or C without active infection are eligible * Autoimmune diseases (such as systemic lupus erythematosus, rheumatoid rthritis, inflammatory bowel disease, autoimmune thyroid disease), but allow the following diseases to enter the next stage of screening: type I diabetes, skin diseases without systemic treatment (such as vitiligo, psoriasis) * 14 days before the first dose, the patient had an active infection that required systemic treatment * Inability to understand or may not comply with test requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| unacceptable toxicity | 1 year | Unacceptable toxicity is defined as any of the following toxicities: \>1 episode of grade 3/4 neutropenia or thrombocytopenia \<75,000/μL (despite prior dose reduction) during chemoradiation any toxicity that results in \>2 week cumulative delay in chemoradiation any toxicity that is attributed to durvalumab which results in a delay of \>8 weeks in surgery, i.e. surgery \>16 weeks from the end of radiation, for a potentially operable patient any reason that is attributed to durvalumab which leads to death within 30 days of surgery |
| pathologic complete response rate, pCR | 1 year | — |
| major pahological response, MPR | 1 year | — |
Countries
China
Contacts
Primary Contactji yongling, MD
Outcome results
None listed